MetabolicHuman RCT
Retatrutide: what the trials show so far, and what is still a press release
Peer-reviewed trials show 24% weight loss at 48 weeks and large falls in liver fat; the headline 28% phase 3 figure is still company-reported.
Semaglutide
A long-acting GLP-1 receptor agonist and licensed medicine, backed by large randomised trials for weight, diabetes, heart and kidney outcomes.
- Also known as
- Ozempic, Wegovy, Rybelsus, NN9535
- Area
- Metabolic
- Status
- Prescription medicine approved in the UK and US (Ozempic, Wegovy, Rybelsus)
Articles on Semaglutide
MetabolicHuman RCT
Cagrilintide and CagriSema: what the amylin trials found
Alone, cagrilintide cut weight by about 11% in 26 weeks; paired with semaglutide it reached 20% at 68 weeks, but lost a head-to-head against tirzepatide.
MetabolicHuman RCT
SELECT: semaglutide cut major heart events by 20% in people who already had heart disease
In 17,604 adults with obesity and existing cardiovascular disease but no diabetes, semaglutide lowered major cardiac events from 8.0% to 6.5% over about three years.
MetabolicHuman RCT
Tirzepatide: what SURMOUNT and SURPASS found
Around 20% average weight loss at 72 weeks, a head-to-head win over semaglutide, and heart-outcome data that matched rather than beat an older GLP-1 drug.
MetabolicHuman RCT
STEP 1: what the semaglutide 2.4 mg obesity trial actually found
Weekly semaglutide cut body weight by 14.9% over 68 weeks against 2.4% on placebo. Most of that came back within a year of stopping.
MetabolicHuman RCT
Semaglutide: what the big trials actually showed
About 15% weight loss at 68 weeks, fewer heart attacks and slower kidney decline in large trials, with stomach side effects, gallbladder risk and weight regain on stopping.